Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,204 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Effects Clear all
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

NCT02884206
View directory record Official record
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery

NCT01330433
View directory record Official record
Conditions
Congenital Heart Defect, Surgery-Induced Tissue Adhesions, Hemorrhage
Interventions
CoSeal Surgical Spray Group
Device
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Effect of Probiotic Supplementation on Endothelial Function

NCT01952834
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
GoodBelly Probiotic, Vancomycin
Dietary Supplement · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Milwauke, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 22, 2026, 6:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Controlled Study to Investigate the Effect of Multi-wave Light Emitting Diode (LED) Bed on Blood Pressure and Endothelial Function

NCT04006158
View directory record Official record
Conditions
Hypertension
Interventions
LED bed
Device
Lead sponsor
LED Intellectual Properties, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rockdale, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 22, 2026, 6:09 AM EDT
Terminated Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

NCT03759678
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
9,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
125
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 22, 2026, 6:09 AM EDT
Completed No phase listed Observational

Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study

NCT02924363
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Cardiac MRI with or without contrast dye, Blood sample
Diagnostic Test
Lead sponsor
Dipan Shah
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 1 Interventional

The Effect of Action Control Based Intervention on Adherence After Cardiac Rehabilitaiton

NCT00602485
View directory record Official record
Conditions
Heart Failure
Interventions
Action Control Education
Other
Lead sponsor
Summa Health System
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

NCT00093249
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 22, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Effects of Prenatal Methamphetamine Exposure

NCT04616625
View directory record Official record
Conditions
Methamphetamine Abuse, Newborn Complication | Patient | Neonatalology
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Marysville, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 22, 2026, 6:09 AM EDT
Completed No phase listed Observational

The Effect of Fontan Fenestration Closure on Hepatic Stiffness

NCT03481985
View directory record Official record
Conditions
Single-ventricle, Hepatic Congestion
Interventions
Fenestration status
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Not applicable Interventional

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

NCT05713916
View directory record Official record
Conditions
Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
Interventions
Intervention: Population Health Coordinator
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 22, 2026, 6:09 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

NCT01731990
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Canakinumab (ACZ885), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

NCT02705755
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

DILIPO (DILutIonal HyPOnatremia)

NCT00274326
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting

NCT01276691
View directory record Official record
Conditions
Cardiovascular Risk Factor, C.Medical Procedure; Vascular, Functional or Late, Electrolyte and Fluid Balance Conditions
Interventions
81 mg enteric coated aspirin
Drug
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
40 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 6:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease

NCT00631306
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Jul 22, 2026, 6:09 AM EDT
Terminated Not applicable Interventional

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

NCT05506215
View directory record Official record
Conditions
Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
Interventions
SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
Device
Lead sponsor
PolyNovo Biomaterials Pty Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Castro Valley, California • Fresno, California • Vista, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Phase 4 Interventional Results available

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

NCT02754518
View directory record Official record
Conditions
Heart Failure
Interventions
Entresto
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 22, 2026, 6:09 AM EDT
Completed Not applicable Interventional

Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension

NCT01672840
View directory record Official record
Conditions
Hypertension
Interventions
5g Cocoa Consumption, 10g Cocoa Consumption
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Derby, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 22, 2026, 6:09 AM EDT